Treatment of lichen planopilaris with adalimumab in a patient with hidradenitis suppurativa and rheumatoid arthritis

Alam, Maryam Shayesteh; LaBelle, Brittanie

doi:10.1016/j.jdcr.2019.12.016

Cited by 9 publications

(11 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HLA-B*07:02 facilitates the process of hair follicular autoantigen presentation 5 and CYP1B1 encodes the xenobiotic-and estrogen-processing enzyme. 20 However, in many studies, including ours, a low percentage (4-9%) of genetic inheritance of FFA is reported. The fact that FFA develops later in life supports the role of environmental factors such as sunscreens and leave-on facial products contributing to the disease etiology.…”

Section: Discussionmentioning

confidence: 54%

“…Recent genome‐wide analysis indicated that FFA is associated with major histocompatibility complex class I molecule, HLA‐B*07:02 and missense variant in CYP1B1. HLA‐B*07:02 facilitates the process of hair follicular autoantigen presentation 5 and CYP1B1 encodes the xenobiotic‐ and estrogen‐processing enzyme 20 . However, in many studies, including ours, a low percentage (4–9%) of genetic inheritance of FFA is reported.…”

Section: Discussionmentioning

confidence: 67%

See 1 more Smart Citation

Clinical characteristics, trichoscopy, histopathology and treatment outcomes of frontal fibrosing alopecia in an Asian population: A retro‐prospective cohort study

Panchaprateep

Ruxrungtham

Chancheewa

et al. 2020

The Journal of Dermatology

View full text Add to dashboard Cite

Frontal fibrosing alopecia (FFA) is a distinctive lymphocytic scarring alopecia with rapid increase in prevalence. Most FFA series are retrospectively reported from Caucasians with only few from Asians. The objective of this study was to characterize the clinical, trichoscopic and histopathological findings as well as treatment outcomes. This was a retro‐prospective cohort study of patients diagnosed with FFA from 1 January 2010 to 1 November 2019. All patients were asked to present for re‐examination. Clinical, trichoscopic, histopathological and laboratory data were recorded. A questionnaire was used to investigate hair care, hairstyle and facial skin care compared with age‐matched normal controls. Multivariate analysis was performed in order to clarify factors associated with severity. All 58 FFA patients were female, of whom 27.6% were premenopausal, 37.7% had a history of surgical menopause, 13.8% had thyroid diseases, 69% had eyebrow loss and 32.8% facial papules. On physical examination, 10.3% showed linear pattern, 46.6% diffuse pattern and 43.1% pseudo‐fringe sign. Concomitant lichen planopilaris was found in 25.9%, lichen planus pigmentosus in 24.1% and female pattern hair loss in 48.3%. The most common trichoscopic characteristics in the frontal hairline were lack of follicular ostia (91.4%), perifollicular scales (79.3%) and perifollicular erythema (63.8%). Up to 90% of patients reported FFA as improved or stable after receiving antiandrogen (finasteride or dutasteride) or antimalarial with topical treatment. Multivariate analyses revealed that facial lentiginous macules and trichoscopic perifollicular erythema at the frontal area were FFA severity‐associated factors. “Front puff” Thai hairstyle was associated with FFA, while sunscreens and other cosmetic products were not. In conclusion, diffuse and pseudo‐fringe sign pattern are common in Asian FFA. The most common autoimmune systemic comorbidity is thyroid disease, while common concomitant dermatological diseases are female pattern hair loss, lichen planopilaris and lichen planus pigmentosus. Antiandrogens or antimalarial plus topical treatment are the most useful therapy.

show abstract

Section: Discussionmentioning

confidence: 54%

Section: Discussionmentioning

confidence: 67%

Clinical characteristics, trichoscopy, histopathology and treatment outcomes of frontal fibrosing alopecia in an Asian population: A retro‐prospective cohort study

Panchaprateep

Ruxrungtham

Chancheewa

et al. 2020

The Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…One woman who had refractory FFA and LPP showed improvement after around four to thirteen months of treatment with tildrakizumab (100 mg subcutaneously at week zero, four and subsequently twelve weekly), an anti p19 IL23 monoclonal antibody [ 206 ]. One case of a woman who was receiving adalimumab for hidradenitis suppurativa and rheumatoid arthritis and experienced hair regrowth in the area affected by LPP has been reported [ 207 ].…”

Section: Treatmentmentioning

confidence: 99%

Frontal Fibrosing Alopecia: A Review

Porriño‐Bustamante

Fernández‐Pugnaire

Arias‐Santiago

2021

JCM

View full text Add to dashboard Cite

Frontal fibrosing alopecia is a scarring alopecia, the prevalence of which is increasing worldwide since its first description in 1994. The reason for this emerging epidemic may be a higher exposure to an unknown trigger, although its aethiology and pathogenesis still remain enigmatic. Clinical, trichoscopic, sonographic, and histopathologic findings are allowing clinicians to understand more aspects about this type of cicatricial alopecia. Several treatments have been used in frontal fibrosing alopecia, although the 5-alpha reductase inhibitors seem to be the most promising. The aim of this report is to provide a compilation about the published data regarding frontal fibrosing alopecia in a narrative review.

show abstract

“…Eight of the 12 patients were treated with low level light therapy (LLLT), 8 1/12 with a combination clobetasol, naltrexone, and LLLT, 9 2/12 with platelet-rich plasma (PRP), 10 and 1/12 with adalimumab. 11 Improvement was noted between 3-6 months, 8,9,11 although response time was not documented in the patients treated with PRP. 10…”

Section: Lppmentioning

confidence: 97%

Hair regrowth in cicatricial alopecia: A literature review

Poliner

Tosti

2021

The Journal of Dermatology

View full text Add to dashboard Cite

Cicatricial alopecias (CA) is a term for a group of subtypes of hair loss in which the hair follicle is destroyed by an unknown inflammatory mechanism. 1,2 Clinically, CA results in loss of the follicular ostia. 1,3 There are three main groups of CA that are grouped based on the perifollicular inflammatory response: primary neutrophilic, primary lymphocytic, or mixed subtypes. 2 Table 1 displays the inflammatory category in which each subtype belongs. The goal of treatment is to stop the ongoing inflammation through a combination of topical or intralesional corticosteroids, antimalarials, immunosuppressants, and antimicrobials, although a number of other medications, lasers, and other therapies have been trialed in refractory cases. 4 Alopecia can have profound psychosocial ramifications and negatively affect a patient's quality of life and self-esteem. 5,6 Even with treatment, patients usually do not experience hair regrowth. 4 Thus, it is important to counsel patients that the goal of treatment is to stop the ongoing inflammation and prevent further hair loss. This conversation must be undertaken delicately as this can be an incredibly difficult conversion for the patient. However, there have been reports in the literature of hair regrowth following treatment of CA. Thus, the aim of this review is to describe the cases of hair regrowth in CA in the published literature. | ME THODSA primary literature search was completed in August 2020 using the keywords "regrowth", "growth", and "name of each subtype of cicatricial alopecia" (e.g., "frontal fibrosing alopecia" or "lichen planopilaris").The databases searched included: PubMed, Cochrane, and Google Scholar. The subtypes of CA that were included in this search were: lichen planopilaris (LPP), frontal fibrosing alopecia (FFA), Graham-Little Syndrome (GLS), central centrifugal CA (CCCA), discoid lupus erythematous (DLE), follicular mucinosis (FM), keratosis follicularis spinulosa decalvans (KFSD), pseudopelade of Brocq, dissecting cellulitis of the scalp (DCS), folliculitis decalvans (FD), acne keloidalis (AK), acne necrotica (AN), and erosive pustular dermatosis of the scalp (EPDS).Eligibility was determined upon review of the article to determine whether they reported documented, either written or photographed, report of hair regrowth. References from each study were assessed to determine if any fit inclusion criteria. Only studies published in English were included.

show abstract

Treatment of lichen planopilaris with adalimumab in a patient with hidradenitis suppurativa and rheumatoid arthritis

Cited by 9 publications

References 7 publications

Clinical characteristics, trichoscopy, histopathology and treatment outcomes of frontal fibrosing alopecia in an Asian population: A retro‐prospective cohort study

Clinical characteristics, trichoscopy, histopathology and treatment outcomes of frontal fibrosing alopecia in an Asian population: A retro‐prospective cohort study

Frontal Fibrosing Alopecia: A Review

Hair regrowth in cicatricial alopecia: A literature review

Contact Info

Product

Resources

About